Skip to Menu Skip to Search Contact Us Global Websites & Languages Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice

Prove the bioavailability/bioequivalence of your drug candidate with fast, accurate, cost-effective BA/BE clinical trials from SGS.

Clinic pharmavigilance safety

Proving the bioavailability/bioequivalence of a drug candidate with reliable data, on-time and on budget, is a cornerstone for generic companies. With biological drugs now making up a large proportion of new drugs, this poses new challenges to generic companies as their “biosimilars” cannot be seen as true generics. 

Why choose bioavailability/bioequivalence clinical trials from SGS?

We provide you with:

  • A highly beneficial regulatory environment in Belgium, enabling a fast study start within two to three weeks from dossier submission to first subject screened
  • In-depth understanding of EC/CA local requirements and specificities
  • An 88-bed clinical pharmacology unit capacity
  • Bioanalytical laboratories for parallel samples dosing
  • Highly experienced biostatistics and PK groups to design studies and analyse data

With over 35 years of experience in early clinical trials, and unmatched Phase 1 expertise, we have the resources and facilities to deliver your bioavailability/bioequivalence clinical trials quickly and accurately.

Contact us today to discuss how we can help with your bioavailability/bioequivalence and biosimilar clinical trials.